> top > docs > PubMed:24991400 > annotations

PubMed:24991400 JSONTXT

Annnotations TAB JSON ListView MergeView

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 146-409 DRI_Outcome denotes BACKGROUND: Individual studies have assessed the impact of standard prophylactic therapy with 5-hydroxytryptamine receptor antagonists (5-HT3RAs) for chemotherapy-induced nausea and vomiting (CINV) on cost and utilization, but no synthesis of the findings exists.
T2 410-562 DRI_Background denotes OBJECTIVE: To systematically review published literature on costs and utilization associated with CINV prophylaxis with palonosetron and other 5-HT3RAs.
T3 1130-1440 DRI_Approach denotes We included records published (full-length articles after 1997 and conference presentations after 2010) in English and with human patients, reporting data on cost and utilization (rescue medication, outpatient and inpatient services) associated with the use of 5-HT3RAs for the treatment or prevention of CINV.
T4 1705-1793 DRI_Background denotes The studies vary in designs, patients, 5-HT3RA regimens, and the definition of outcomes.
T5 2069-2213 DRI_Background denotes Fewer patients receiving palonosetron versus with ondansetron or other 5-HT3RAs required rescue medication or used outpatient or inpatient care.
T6 2214-2366 DRI_Background denotes In Europe and in Canada, the total pharmacy costs and use of rescue medications reported are lower for patients receiving prophylaxis with palonosetron.
T7 2666-2774 DRI_Approach denotes Therefore, the use of palonosetron as a standard treatment may lead to reduced service utilization for CINV.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 317-323 HP_0002018 denotes nausea
T2 328-336 HP_0002013 denotes vomiting

Allie

Id Subject Object Predicate Lexical cue
SS1_24991400_2_0 240-280 expanded denotes 5-hydroxytryptamine receptor antagonists
SS2_24991400_2_0 282-290 abbr denotes 5-HT3RAs
SS1_24991400_2_1 296-336 expanded denotes chemotherapy-induced nausea and vomiting
SS2_24991400_2_1 338-342 abbr denotes CINV
AE1_24991400_2_0 SS1_24991400_2_0 SS2_24991400_2_0 abbreviatedTo 5-hydroxytryptamine receptor antagonists,5-HT3RAs
AE1_24991400_2_1 SS1_24991400_2_1 SS2_24991400_2_1 abbreviatedTo chemotherapy-induced nausea and vomiting,CINV

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 158-409 BACKGROUND denotes Individual studies have assessed the impact of standard prophylactic therapy with 5-hydroxytryptamine receptor antagonists (5-HT3RAs) for chemotherapy-induced nausea and vomiting (CINV) on cost and utilization, but no synthesis of the findings exists.
T2 421-562 OBJECTIVE denotes To systematically review published literature on costs and utilization associated with CINV prophylaxis with palonosetron and other 5-HT3RAs.
T3 572-1440 METHODS denotes PubMed and the National Institute for Health Research Centre for Reviews and Dissemination databases, conferences of 4 organizations (ie, Academy of Managed Care Pharmacy, American Society of Clinical Oncology, International Society for Pharmacoeconomics and Outcomes Research, and Multinational Association of Supportive Care in Cancer), and the bibliographies of relevant articles were queried for the medical subject headings and key terms of "ondansetron," "granisetron," "palonosetron," "dolasetron mesylate," "costs," "cost analysis," and "economics." We included records published (full-length articles after 1997 and conference presentations after 2010) in English and with human patients, reporting data on cost and utilization (rescue medication, outpatient and inpatient services) associated with the use of 5-HT3RAs for the treatment or prevention of CINV.
T4 1450-2366 RESULTS denotes Of the 434 identified studies, 32 are included in the current analysis: 7 studies report costs, 18 report utilization, and 7 studies report both. The costs are reported in US dollars (7 studies), in Euros (5 studies), and in Canadian dollars (2 studies). The studies vary in designs, patients, 5-HT3RA regimens, and the definition of outcomes. The US studies report higher drug costs for CINV prophylaxis with palonosetron compared with ondansetron, lower medical outpatient and inpatient costs for palonosetron versus other 5-HT3RAs, and higher acquisition costs for palonosetron versus ondansetron or other 5-HT3RAs. Fewer patients receiving palonosetron versus with ondansetron or other 5-HT3RAs required rescue medication or used outpatient or inpatient care. In Europe and in Canada, the total pharmacy costs and use of rescue medications reported are lower for patients receiving prophylaxis with palonosetron.
T5 2380-2774 CONCLUSIONS denotes This analysis shows that prophylaxis with palonosetron for the treatment of CINV is associated with higher acquisition treatment costs, but also with lower use of rescue medications and outpatient and inpatient services compared with ondansetron or other 5-HT3RAs in the United States. Therefore, the use of palonosetron as a standard treatment may lead to reduced service utilization for CINV.